Hormonal Drivers

Hormonal mechanisms underpin many obesity phenotypes with specific actionable therapies. The session covers setmelanotide (Imcivree) for hypothalamic obesity and rare monogenic conditions (LEPR, POMC, PCSK1, BBS), ghrelin pathways and leptin physiology, Cushing syndrome screening in unexplained weight gain, hypothyroidism and weight myths, PCOS-related obesity management with GLP-1, and the metabolic-reproductive interface. Discussion addresses Hashimoto thyroiditis and metabolic effects, sex hormones (testosterone, estradiol, progesterone) and obesity, growth hormone deficiency and obesity, perimenopause and menopause weight gain, and emerging targets including GDF15 and FGF21.